Elkomy MH, Zaki RM, Alsaidan OA, Elmowafy M, Zafar A, Shalaby K, et al
References to clinical trials, body-weight outcomes, glucose-related measures, or other human endpoints are not claims about this product and do not indicate that it is intended for human or animal use
Potency: In animal studies, Dihexa has been shown to be millions of times more potent than BDNF (Brain-Derived Neurotrophic Factor) at stimulating synapse formation
The proportions of adolescents with a PGI-C response of moderately improved or much improved ranged from 45% to 61% in the 30mg ritlecitinib groups at week 24 vs 10% to 22% in placebo groups.22 Pediatric patients In pediatric patients, a recent phase 1 study characterized the pharmacokinetic and safety parameters of ritlecitinib in patients with AA aged 6 to 0.05)
Some practitioners recommend combining both for comprehensive support, though this adds cost